Risk for second malignancies in non-Hodgkin’s lymphoma survivors: a meta-analysis

Pirani, Monica; Marcheselli, Raffaella; Marcheselli, Luigi; Bari, Alessia; Federico, Massimo; Sacchi, Stefano

doi:10.1093/annonc/mdq697

Cited by 75 publications

(81 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with NHL are at a higher risk for secondary malignant neoplasms (SMNs) than the general population and a combined modality of treatment was significantly associated with the risk for overall SMNs in a meta-analysis [17]. In our study, 1 patient developed AML during follow-up after treatment, even though he was given only abbreviated chemotherapy.…”

Section: Discussionmentioning

confidence: 72%

Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection

Yoon

Lee

et al. 2014

Blood Res

View full text Add to dashboard Cite

BackgroundAbbreviated chemotherapy followed by radiotherapy or full cycles of chemotherapy is recommended as a standard treatment for limited-stage (LS) diffuse large B-cell lymphoma (DLBCL). After complete resection of tumors, however, Burkitt and childhood B-cell Non-Hodgkin lymphoma show favorable outcomes, even after abbreviated chemotherapy of only 2 or 3 cycles. We investigated the effectiveness of abbreviated chemotherapy in patients with LS DLBCL after complete tumor resection.MethodsWe retrospectively reviewed 18 patients with LS DLBCL who underwent complete tumor resection followed by either 3 or 4 cycles of chemotherapy between March 2002 and May 2010.ResultsWith a median follow-up period of 57.9 months (range, 31.8-130.2 months), no patients experienced disease relapse or progression; however, 1 patient experienced secondary acute myeloid leukemia during follow-up. The 5-year progression-free survival rate and overall survival rate were 93.3% and 94.1%, respectively.ConclusionThese results warrant further investigation into abbreviated chemotherapy as an alternative treatment for patients who have undergone complete resection of LS DLBCL.

show abstract

Section: Discussionmentioning

confidence: 72%

Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection

Yoon

Lee

et al. 2014

Blood Res

View full text Add to dashboard Cite

show abstract

“…For the meta-analysis,14 we initially identified 1,521 potentially eligible studies. Based on the inclusion criteria, 23 papers were analysed; of these, 21 studies contributed to principal meta-analysis on the risk of developing SMN, and 19 provided risk factors for specific cancer types.…”

Section: Resultsmentioning

confidence: 99%

“…The meta-analysis14 was performed by reviewing papers about secondary neoplasia selected from electronic databases (Medline and Embase) to provide a global quantitative assessment of the risk for SMN. Search strategy, selection criteria, data extraction, and statistical analysis are extensively described in the original article.…”

Section: Design and Methodsmentioning

confidence: 99%

“…In addition, we have recently performed a meta-analysis to estimate the pooled relative risk (RR) of secondary malignant neoplasm (SMN) in NHL survivors14 and the association between chemotherapeutic or radiotherapeutic approaches and site-specific cancers, focusing our attention on MDS and AML. Finally, we compared meta-analysis results with those obtained from MCR data.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapy-Related Myeloid Neoplasm in Non-Hodgkin Lymphoma Survivors

Bari

Marcheselli²,

Marcheselli³

et al. 2011

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Relatively little data on secondary cancers is available regarding patients treated for non-Hodgkin lymphoma (NHL), compared with those treated for Hodgkin lymphoma. Evolving treatment regimens have improved survival outcomes for NHL patients. As a result of this improvement, secondary malignancies are becoming an important issue in NHL survivors. This review aims to report data on this topic previously published by our group, adding unpublished results from the Modena Cancer Registry (MCR). We recently performed four studies about secondary neoplasms in NHL survivors: two studies analysing the risk of secondary neoplasms in patients treated for indolent and aggressive NHL; a meta-analysis of 23 studies investigating the risk of secondary malignant neoplasm (SMN) after NHL treatment; and a still-unpublished study evaluating the incidence of therapy-related myeloid neoplasm (t-MN) in patients treated for NHL (from the MCR database). The first two studies analysed 563 patients with indolent NHL and 1280 patients with diffuse large B-cell lymphoma (DLBCL) enrolled in the Gruppo Italiano Studio Linfomi (GISL) trials. Results showed that the cumulative incidence of secondary tumours was 10.5% at 12 years for indolent NHL and 8.2% at 15 years for DLBCL. Results of the meta-analysis indicated that NHL patients experienced a 1.88-fold increased risk for SMN compared with the general population; the standardized incidence risk (SIR) for secondary acute myeloid leukaemia (AML) was 11.07. Based on data from the MCR from 2000 through 2008, we found that the SIR was 1.63 for developing a secondary malignancy after NHL, and 1.99 for developing secondary haematological malignancies. Regarding myelodysplastic syndrome and/or AML incidence, nine NHL patients developed t-MN with a higher risk than expected (SIR 8.8, 95% CI: 4.0–16.6). In conclusion, patients treated for NHL are at increased risk of developing SMN. Regarding t-MN, data from the meta-analysis and the MCR demonstrate an excessive risk of developing AML (SIR 11.07 and 5.7, respectively) compared with solid SMN after treatment for NHL. Thus long-term monitoring should be considered for NHL survivors.

show abstract

“…Compared to the general population, NHL patients have a 1.88-fold higher risk of developing second malignancies (2). The incidence of concomitant appearance of NHL and renal cell carcinoma (RCC) was also proven to be higher than anticipated (3).…”

Section: Introductionmentioning

confidence: 99%

Simultaneous occurrence of non-Hodgkin lymphoma, renal cell carcinoma and oncocytoma: A case report

Zabrocka

Sierko

Jelski³

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. We herein report the case of a 74 year-old woman with a diffuse large B-cell lymphoma and bilateral renal masses identified on computed tomography scans during the initial staging process. Following partial bilateral nephrectomy, histopathological examination revealed renal cell carcinoma (RCC) and oncocytoma in the left and the right kidneys, respectively. Shortly afterwards, lymphoma of the left palatine tonsil was diagnosed and the patient received chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP regimen), followed by radiotherapy. Due to metastasis of the RCC to the right breast, pancreas and the area of the left psoas major muscle, systemic treatment with pazopanib was commenced. To the best of our knowledge, this is the first reported case of simultaneous diagnosis of non-Hodgkin lymphoma (NHL), RCC and oncocytoma. The aim of this study was to review the related literature, discuss issues regarding the management of this unusual case and identify possible common etiopathological mechanisms underlying the simultaneous occurrence of NHL, RCC and oncocytoma.

show abstract

Risk for second malignancies in non-Hodgkin’s lymphoma survivors: a meta-analysis

Abstract: Our results indicate that NHL patients experience a higher risk for SMNs than the general population and that various treatments have different impact on RR. More information will be necessary to evaluate possible interactions with genetic susceptibility and environmental exposure.

Cited by 75 publications

References 82 publications

Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection

Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection

Therapy-Related Myeloid Neoplasm in Non-Hodgkin Lymphoma Survivors

Simultaneous occurrence of non-Hodgkin lymphoma, renal cell carcinoma and oncocytoma: A case report

Contact Info

Product

Resources

About